Keytruda: The gift that keeps on giving at Merck
For drug companies, immunotherapy can seem crowded these days. But there’s no question that, in terms of sales, Merck’s Keytruda is pulling away from the pack. In the third quarter of 2018, sales of the checkpoint inhibitor reached $1.9 billion — 18 percent of Merck’s total revenue.
But is it a good idea to have so much riding on one drug?
Merck’s CFO Rob Davis contends that the pharma giant’s portfolio is more diverse than it may look. He also argued the pipeline is strong. “I think people under-appreciate the pillars of growth we have outside of Keytruda because the shadow it casts is so large,” he said.
Read more.
But is it a good idea to have so much riding on one drug?
Merck’s CFO Rob Davis contends that the pharma giant’s portfolio is more diverse than it may look. He also argued the pipeline is strong. “I think people under-appreciate the pillars of growth we have outside of Keytruda because the shadow it casts is so large,” he said.
Read more.
.png)
No hay comentarios:
Publicar un comentario